TY - JOUR
TI - A clinicopathological study of the expression of extracellular matrix
components in urothelial carcinoma
AU - Ioachim, E
AU - Michael, M
AU - Stavropoulos, NE
AU - Kitsiou, E and
AU - Salmas, M
AU - Malamou-Mitsi, V
JO - BJU international (Papier)
PY - 2005
VL - 95
TODO - 4
SP - 655-659
PB - Wiley
SN - null
TODO - 10.1111/j.1464-410X.2005.05357.x
TODO - tenascin; fibronectin; collagen type IV; laminin; bladder cancer
TODO - OBJECTIVE
To measure the immunohistochemical expression of the extracellular
matrix (ECM) components tenascin, fibronectin, collagen type IV and
laminin in urothelial carcinomas, and to correlate their expression with
clinicopathological features to clarify the prognostic value of these
molecules and their role in tumour progression.
MATERIALS AND METHODS
Tumour specimens obtained during transurethral resection of bladder
tumour (TURBT) from 103 patients (82 men and 2 1 women, mean age 66.7
years, range 27-89) were studied retrospectively. The expression of
tenascin, fibronectin, collagen type IV and laminin was correlated with
clinicopathological features (tumour grade and stage, multiplicity,
simultaneous in situ component, the proliferative activity as estimated
by the two proliferation associated indices, Ki-67 and proliferating
cell nuclear antigen, the recurrence rate, and the progression of
invading tumour). Specimens investigated for tenascin expression from
patients with superficial bladder cancers were categorized into 28
treated by TURBT only and 53 who had TURBT followed by intravesical
instillations of interferon.
RESULTS
Cytoplasmic tenascin expression was detected in tumour cells in 20% of
specimens. Tenascin was expressed in the tumour stroma in 76% of
specimens, and was positively correlated with tumour grade and stage.
Stromal tenascin expression was positively correlated with proliferative
activity, and with the expression of filbronectin and collagen type IV.
Fibronectin was expressed in the tumour stroma in 89% of specimens and
was positively correlated with tumour stage, proliferative activity, and
expression of collagen type IV and laminin. Collagen type IV was
expressed in 93% of specimens, and was positively correlated with
tumour grade and stage. Laminin was expressed in 78% of specimens and
had no significant correlation with the clinicopathological features.
Patients treated with TURBT alone and who had low levels of tenascin had
a longer tumour-free interval than those with high levels of tenascin.
CONCLUSION
Levels of tenascin might be valuable for predicting the risk of early
recurrence. The expression of tenascin, filbronectin and collagen type
IV seems to be correlated with more aggressive tumour behaviour.
Furthermore, their interrelationships could indicate that they are
involved in the remodelling of bladder cancer tissue, probably
influencing tumour progression.
ER -